

Newport Beach and Birch Street

Clinical Research Treatment Trial Flowchart

**AML NEWLY DIAGNOSED: NON-INTENSIVE****UCI 21-216**

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar

Coord: S. Osorio

Accrual: 2/5

CLL NEWLY DIAGNOSED: HIGH RISK**SWOG S1925**

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs

Coord: M. Kunicki

Accrual: 4/10



GASTRIC/GEJ: NEOADJUVANT

UCI 21-191

(SOC therapy with ctDNA testing)

PI: Dayyani
Coord: A. Luna
Accrual: 5/20

NON-TREATMENT/BASIC SCIENCE

UCI 18-136

PI: Parajuli
Coord: B. Sanchez
Accrual: 76/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli
Coord: B. Sanchez
Accrual: 49/75

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended



1L METASTATIC

2L METASTATIC

3L METASTATIC

ETCTN 10546 (TNBC)

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)

PI: Parajuli; Coord: A. Chavez

Accrual: 1/5



HCC: LOCOREGIONAL

UCI 19-49

Cabo + Ipi/Nivo + TACE

PI: Dayyani
Coord: B. Nguyen
Accrual: 24/35

HCC: 1-3L

UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani
Coord: H. Nguyen
Accrual: 9/10

PANCREATIC: BORDERLINE/LOCALLY ADVANCED

ETCTN 10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani
Coord: S. Duong
Accrual: 8/13



MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 97/110



Neo-adjuvant or Adjuvant HNSCC

HN009

Cisplatin Q3 weeks vs Weekly
Locally Advanced HNSCC

Coord: A. Reipolska
Accrual: 1/5



CLDN18.2

UCI 21-10

Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani

Coord: K. Ghio

Accrual: 21/27